Zabdeno Europska Unija - hrvatski - EMA (European Medicines Agency)

zabdeno

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Геморрагическая groznice ebole - cjepiva - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Mvabea Europska Unija - hrvatski - EMA (European Medicines Agency)

mvabea

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - Геморрагическая groznice ebole - cjepiva - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

SIMPONI 50 mg/0.5 mL rastvor za injekciju u napunjenoj šprici Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

simponi 50 mg/0.5 ml rastvor za injekciju u napunjenoj šprici

merck sharp & dohme bh d.o.o. - golimumab - rastvor za injekciju u napunjenoj šprici - 50 mg/0.5 ml - 0,5 ml rastvora za injekciju u napunjenoj šprici sadrži: 50 mg golimumaba

SIMPONI 50 mg/0.5 mL rastvor za injekciju u napunjenom penu Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

simponi 50 mg/0.5 ml rastvor za injekciju u napunjenom penu

merck sharp & dohme bh d.o.o. - golimumab - rastvor za injekciju u napunjenom penu - 50 mg/0.5 ml - 0,5 ml rastvora za injekciju u napunjenom penu sadrži: 50 mg golimumaba

Rybrevant Europska Unija - hrvatski - EMA (European Medicines Agency)

rybrevant

janssen-cilag international n.v.    - amivantamab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Lextemy Europska Unija - hrvatski - EMA (European Medicines Agency)

lextemy

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

ABEVMY 25 mg/1 mL Koncentrat za otopinu za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

abevmy 25 mg/1 ml koncentrat za otopinu za infuziju

viatris bh d.o.o. - bevacizumab - koncentrat za otopinu za infuziju - 25 mg/1 ml - 1 bočica sa 16 ml koncentrata za otopinu za infuziju sadrži: 400 mg bevacizumaba (25 mg/ml)

ABEVMY 25 mg/1 mL Koncentrat za otopinu za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

abevmy 25 mg/1 ml koncentrat za otopinu za infuziju

viatris bh d.o.o. - bevacizumab - koncentrat za otopinu za infuziju - 25 mg/1 ml - 1 bočica sa 4 ml koncentrata za otopinu za infuziju sadrži: 100 mg bevacizumaba (25 mg/ml)

Carvykti Europska Unija - hrvatski - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - multipli mijelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Opdualag Europska Unija - hrvatski - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.